Important and exciting news from the RAFT trial.
August 23, 2022
Update: As of 7/19/2022, the RAFT trial is no longer enrolling participants with fetal bilateral renal agenesis into the intervention arm of the study. The trial is still enrolling participants with other causes of fetal renal failure and anhydramnios in the intervention arm. In addition, the trial is still enrolling all diagnoses in the expectant management arm.
July 19, 2022
As of 7/19/2022, the RAFT trial is no longer enrolling participants with fetal bilateral renal agenesis. The trial is still enrolling participants with causes of fetal renal failure and anhydramnios in the intervention arm.
October 26, 2020
We are pleased to announce that Columbia, UCSF, CHOP, and Colorado are now accepting intervention and expectant management patients.
September 24, 2020
After a pause for the COVID-19 pandemic, the RAFT trial is once again recruiting new patients. Johns Hopkins and Stanford are actively recruiting with other sites around the country ready to come on board in the next few weeks
May 23, 2020
Despite the COVID-19 pandemic work continues behind the scenes to onboard other centers around the country. These centers include Stanford fetal center, UCSF fetal center, USC fetal center, CHOP fetal center, Mayo fetal center, Columbia fetal center. Once these RAFT centers are live, burdensome travel for patients and their families will be dramatically decreased. Recruitment into the trial will resume when public health officials, individual sites and the Johns Hopkins Institutional Review Board agree that doing so is safe.
The RAFT trial has received R01 funding from the National Institutes of Health. Specifically the Eunice Shriver National Institute of Child Health and Development is sponsoring the trial. Dr. Eric Jelin, the Director of the Johns Hopkins Children’s Center Fetal Program, is the lead principal investigator of the trial. Dr. Jelin works closely with Dr. Ahmet Baschat’s Center for Fetal Therapy at Johns Hopkins Hospital. Yair Blumenfeld is the local principal investigator at Stanford which has already begun recruiting patients on the West Coast.